OTCMKTS:CPMV Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis $0.50 -0.01 (-1.07%) As of 08/19/2025 10:21 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Mosaic ImmunoEngineering Stock (OTCMKTS:CPMV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPMV alerts:Sign Up Key Stats Today's Range$0.50▼$0.5150-Day Range$0.30▼$0.5452-Week Range$0.25▼$1.00Volume2,841 shsAverage Volume338 shsMarket Capitalization$3.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California. Read More Receive CPMV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mosaic ImmunoEngineering and its competitors with MarketBeat's FREE daily newsletter. Email Address CPMV Stock News HeadlinesMosaic ImmunoEngineering, Inc. (CPMV) - Yahoo FinanceJune 27, 2025 | au.finance.yahoo.comMosaic ImmunoEngineering, Inc. (CPMV)November 17, 2024 | finance.yahoo.comNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. | Brownstone Research (Ad)Mosaic Co.November 5, 2024 | wsj.comMosaic ImmunoEngineering (OTC:CPMV) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comCowpea Mosaic Virus Nanoparticles Show Promise in Preventing Metastatic CancersMay 14, 2024 | msn.comNanoparticle plant virus treatment shows promise in fighting metastatic cancers in miceMay 13, 2024 | msn.comMosaic ImmunoEngineering Inc.: Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.April 29, 2024 | finanznachrichten.deSee More Headlines CPMV Stock Analysis - Frequently Asked Questions How have CPMV shares performed this year? Mosaic ImmunoEngineering's stock was trading at $0.7012 at the start of the year. Since then, CPMV shares have decreased by 29.0% and is now trading at $0.4980. How were Mosaic ImmunoEngineering's earnings last quarter? Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) released its quarterly earnings results on Tuesday, August, 19th. The company reported ($0.02) earnings per share (EPS) for the quarter. How do I buy shares of Mosaic ImmunoEngineering? Shares of CPMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mosaic ImmunoEngineering own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mosaic ImmunoEngineering investors own include BioNxt Solutions (BNXTF), Defense Metals (DFMTF), C3.ai (AI), Applied Genetic Technologies (AGTC), Agile Therapeutics (AGRX), AgriFORCE Growing Systems (AGRI) and Company Calendar Last Earnings8/19/2025Today8/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CPMV CIK836564 Webwww.ptsc.com Phone(657) 208-0890Fax760-547-2705Employees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$920 thousand Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,117.89% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.94) per share Price / Book-0.53Miscellaneous Outstanding Shares7,240,000Free Float1,377,000Market Cap$3.61 million OptionableNot Optionable Beta-1.18 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:CPMV) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWinning the AI WarWhat’s really driving the trade wars, reshoring, and sweeping executive orders? According to Porter Stansberry...Porter & Company | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSeptember 16 Could Crush Your Tech StocksMillions of investors are piled into the same megacap tech stocks—Nvidia, Microsoft, Amazon, Tesla. But Wall S...InvestorPlace | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mosaic ImmunoEngineering Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mosaic ImmunoEngineering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.